Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors

Monoclonal antibodies (mAbs) have become a successful therapeutic approach in cancer. However, some patients do not achieve long-term clinical benefit and most mAbs only exert modest effects as monotherapies. Therefore, combinations with chemotherapy are currently being investigated. Emerging studie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Yélamos, José, Galindo, Miguel, Navarro, Judith, Albanell, Joan, Rovira, Ana, Rojo, Federico, Oliver, Javier
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2015
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4760278/
https://ncbi.nlm.nih.gov/pubmed/26942084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1065370
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars